undefined
EUTM file information

018419228

AURORA


March 8, 2021

Trademark Summary

The trademark AURORA was filed by Immunocore Limited, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on April 5, 2021, and received one opposition filed on July 5, 2021 by BELLA AURORA LABS, S.A. on (a) Identity of marks and Goods and Services, (b) Likelihood of confusion. the opponent was represented by PONS IP, S.A. and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued July 5, 2021

The application was filed in English, and English was also language of all opposition proceedings (French was selected as the second language).


Goods And Services

  • The mark was filed in class 5 with following description of goods:
    1. Pharmaceutical preparations excluding ophthalmic pharmaceutical preparations
    2. Biological preparations for the treatment of cancer
    3. Biological preparations for the treatment of viral infections
    4. Biological preparations for the treatment of autoimmune diseases
    5. Biological preparations for medical use
    6. Immunotherapeutic drugs
    7. Reagents for medical use
    8. Diagnostic preparations
    9. Diagnostic reagents for medical use
    10. Preparations and reagents used in connection with drug discovery, namely the identification of pharmaceutical targets and/or the development of molecules to be used for medicinal or therapeutic purposes
    11. Preparations and reagents used in connection with protein engineering and biological drug development.
  • The mark was filed in class 42 with following description of goods:
    1. Scientific and technological services and research and design relating thereto
    2. Pharmaceutical research and development services
    3. Pharmaceutical testing and clinical trials
    4. Research and development in the biotechnology field
    5. Drug discovery, namely the identification of pharmaceutical targets and/or the development of molecules to be used for medicinal or therapeutic purposes
    6. Protein engineering and biological drug development
    7. Provision of information and consultancy in relation to the aforesaid services.